Dianthus Therapeutics, Inc. /DE/ Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Dianthus Therapeutics, Inc. /DE/ (DNTH) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value of $2.14 million as of 2020-12-31, per its 10-K filed 2021-03-03.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue · last filed 2021-03-03
- 2020-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $2.14M.
- 2019-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $29.63M.
- 2018-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $526.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value |
|---|---|
| 2020-12-31 | $2.14M 10-K · filed 2021-03-03 |
| 2019-12-31 | $29.63M 10-K · filed 2020-03-03 |
| 2018-12-31 | $526.00K 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |